Barclays lowered the firm’s price target on OptimizeRx (OPRX) to $5 from $11 and keeps an Equal Weight rating on the shares. The stock dropped 17% on a Q3 headline miss and lowered fiscal 2024 guidance attributable to a shift away from direct-to-consumer managed services, the analyst tells investors in a research note. The firm thinks fiscal 2025 will likely be a transition year for OptimizeRx.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX: